Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Good financial results growth rate 19.2% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-6.8%)
  • Dividend yield for the last twelve months 5.3%
  • Free cash flow yield 9.6% (LTM)
  • Share price is 17.9% higher than minimum and 42.4% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (20.5x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (-1.6%)46.745
year average price 52.68  


year start price 49.80 2024-09-05

max close price 63.11 2025-03-10

min close price 43.31 2025-07-31

current price 46.75 2025-09-04
Common stocks: 2 111 517 922

Dividend Yield:  5.3%
FCF Yield LTM: 9.6%
EV / LTM EBITDA: 20.5x
EV / EBITDA annualized: 19.3x
Last revenue growth (y/y):  +0.6%
Last growth of EBITDA (y/y):  +37.9%
Historical revenue growth:  +0.5%
Historical growth of EBITDA:  -14.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 98 703
Net Debt ($m): 36 640
EV (Enterprise Value): 135 343
EBITDA LTM ($m): 6 595
EV / LTM EBITDA: 20.5x
Price to Book: 5.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-02zacks.com

Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?

2025-09-01forbes.com

7 Big Yields From The Beat-Up Healthcare Sector

2025-08-29businesswire.com

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

2025-08-27zacks.com

Will Camzyos Strengthen BMY's Cardiovascular Portfolio?

2025-08-22zacks.com

BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?

2025-08-13zacks.com

Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?

2025-08-04seekingalpha.com

Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity

2025-08-04seekingalpha.com

Bristol-Myers Squibb: Buy The Weakness

2025-08-02seekingalpha.com

Bristol-Myers Squibb: Declines Have Gone Too Far

2025-08-01fool.com

Bristol Myers (BMY) Q2 EPS Jumps 36%
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data